Study objective -To estimate quantitatively the impact of the quality of mammographic screening (in terms of sensitivity and specificity) on the effects and costs of nationwide breast cancer screening. Design -Three plausible "quality" scenarios for a biennial breast cancer screening programme for women aged 50-69 in Germany were analysed in terms of costs and effects using the Microsimulation Screening Analysis model on breast cancer screening and the natural history ofbreast cancer. Firstly, sensitivity and specificity in the expected situation (or "baseline" scenario) were estimated from a model based analysis of empirical data from 35 000 screening examinations in two German pilot projects. In the second "high quality" scenario, these properties were based on the more favourable diagnostic results from breast cancer screening projects and the nationwide programme in The Netherlands. Thirdly, a worst case, "low quality" hypothetical scenario with a 25% lower sensitivity than that experienced in The Netherlands was analysed. Setting -The epidemiological and social situation in Germany in relation to mass screening for breast cancer. Results -In the "baseline" scenario, an 11% reduction in breast cancer mortality was expected in the total German female population, ie 2100 breast cancer deaths would be prevented per year. It was estimated that the "high quality" scenario, based on Dutch experience, would lead to the prevention of an additional 200 deaths per year and would also cut the number of false positive biopsy results by half. The cost per life year gained varied from Deutsche mark (DM) 15 000 in the "high quality" scenario to DM 21000 in the "low quality" setting. Conclusions -Up to 20% of the total costs of a screening programme can be spent on quality improvement in order to achieve a substantially higher reduction in mortality and reduce undesirable side effects while retainiing the same cost effectiveness ratio as that estimated from the German data. (J7 Epidemiol Community Health 1997;51: 180-186) Breast cancer screening for women aged 50 and over is being implemented in a large number of European countries. These programmes aim to achieve a relatively high level of quality by means of strict organisation, training, and evaluation.'2 The definition of screening quality is often narrowed down to two propertiessensitivity (ie the capability of accurately detecting cancer at a screening examination and specificity (the ability to pinpoint accurately those women without breast cancer). High sensitivity can be assumed to be one of the key elements in achieving a reduction in breast cancer mortality, while high specificity will reduce the negative side effects of screening.3
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The nationwide programmes in the United Kingdom and The Netherlands have made a good start in providing facilities which ensure high standards. It is not certain, however, that these high standards can be achieved in all countries or programmes, especially where the organisation of screening is not centralised. Where screening is carried out in the private practices of gynaecologists or radiologists it may be of poorer quality than that undertaken in specialist screening units. The reasons for this are that in a decentralised screening setting quality control is less easily achieved, radiologists who are not specialists in this area may be less skilled in screening mammography, and the mammography equipment may be of an inferior quality.
The decentralised health care setting in Germany has occasioned discussion about the introduction of a nationwide breast cancer screening programme. In this study we have estimated the expected sensitivity and specificity for a nationwide German programme, based on the results from the Aurich and Braunschweig pilot projects. Screening performance results predicted by the Microsimulation Screening Analysis (MISCAN) model8 were compared with the observed data in these projects to estimate sensitivity. Since the true extent of the future quality in a decentralised system is ofcourse difficult to assess, we have defined two other sets of plausible quality assumptions as follows: 1 A "high quality" scenario based on the situation in the Dutch nationwide programme; and 2 A hypothetical "low quality" scenario with a 25% lower sensitivity than that experienced in The Netherlands. The impact of these various quality assumptions (sensitivity and specificity) on the outcomes of a screening programme was evaluated and quantified in terms of a reduction in breast cancer mortality and costs and in negative side effects. The results from this study give indications for the cost effectiveness of quality assurance and evaluation.
Methods

THE MISCAN APPROACH
In this study the MISCAN model for screening analysis and evaluation was used.89 The natural history of breast cancer was reflected in this model in four states -one ductal carcinoma in situ DCIS) and three invasive states with increasing tumour size. By incorporating demographic aspects, individual life histories can be generated to simulate a "real life" dynamic population with breast cancer incidence and mortality, and death from other causes. A screening programme can be applied to this population to determine what changes would occur. Various characteristics of screening policies or programmes can be defined, such as screening ages, interval, and attendance. Important screening parameters embedded in the model were the sensitivity and specificity of the screening test and the improvement in prognosis after screen detection.
The sensitivity of a screening examination is an age and state dependent model parameter, defined as the probability of a positive screen result when screening a woman with preclinical breast cancer. Preclinical cancer is defined here as a lesion that has not yet been clinically diagnosed. Specificity is defined as the probability of a negative test result in a woman without preclinical cancer. Given the preclinical prevalences and detection rates as model outcomes, specificity of screening can be modified in the model by adjusting the positive predictive values (PPVs) of the subsequent additional diagnostic steps. In this way, the numbers of diagnostic assessments without breast cancer being diagnosed (false positives) can be determined. Improvement in prognosis due to early detection was defined in the model as the reduction in risk of dying from breast cancer for screen detected cases, and was dependent on age and cancer stage. The estimate of this improvement in prognosis after screening detection was based on the breast cancer mortality reduction reported in the overview ofthe Swedish randomised trials.9 10 The design ofthe analysis on effects and costs of breast cancer screening has been described before.1 ' The demography was based on the 1989 age specific distribution ofthe total German female population; death rates from causes other than breast cancer were based on 1990 data from the former West Germany, combined with less detailed data from the former German Democratic Republic (GDR). Breast cancer mortality rates were calculated on the basis of 1990 data from the former West Germany, incorporating 25% lower rates for the former GDR. 16 The clinical stage distribution of breast cancer was based on published series'718 and assumed not to be different from The Netherlands.'9 Data from the Saarland cancer registry were used to determine the breast cancer incidence at national level.20 Regional differences in incidence were assumed to be negligible on the basis of the regional mortality data for breast cancer.2' Relative survival rates in the model had to be adjusted slightly downwards for all ages, and specifically for the younger age group, to make the simulated breast cancer mortality fit the observed data.
THE GERMAN MODEL: PRECLINICAL DURATION OF BREAST CANCER AND SENSITIVITY
Age specific assumptions on the mean durations of preclinical states in The Netherlands were based on data from the Dutch screening projects in Utrecht and Nijmegen and have been published before.8' The mean duration of preclinical disease was estimated to range from 2.7 (age 50) to 6.2 (age 70) years. Durations for the preclinical stages of breast cancer in Germany were assumed not to be different from those estimated for The Netherlands.
The expected sensitivity of a screening programme in Germany has been assessed from the results oftwo German pilot projects, Aurich and Braunschweig, in the Deutsche Mammographie Studie.6 In these regions, breast cancer screening has been carried out since 1990. Data from 35 000 screening examinations (27 000 of which were first screens) in the first two years (1990.III-1992.III) were Table I Sensitivity in relation to tumour stage, and referral rates (for additional examinations and biopsy) and positive predictive values (PPV) (of a referral for biopsy), for first and subsequent screens as proxy indicators for specificity in three quality scenarios -baseline, high quality and low quality Based on these results, together with the present discussion on quality of screening in Germany and DMS data,6 the expected sensitivity in the baseline scenario was assumed to be 12% less than that experienced in The Netherlands.
In the following parts of the Results section, this scenario will be evaluated and compared with the other two scenarios. diagnosed breast cancer cases, especially in the beginning of the programme when the prevalence of screen detectable cases is relatively high.24 A five year build up period in the programme will cause this increase in annual incidence to be spread more evenly over time.
In the baseline scenario, biennial screening of women aged 50 to 69 in Germany is expected to lead to increases in the total annual incidences (all ages) of 6%, 10%, 6%, and 3.% in the 2nd, 4th, 6th, and 8th years of the programme respectively. The maximum increase is to be expected in the 4th year, when 3900 more women will be diagnosed with breast cancer than in a situation without screening. Different levels of sensitivity are expected to result in similar sequences of increases in annual incidence, with a maximum of 9% in the low quality scenario compared with 11% in the high quality scenario. The present screening programme in The Netherlands is expected to lead to a maximum increase of 15%, mainly because of a higher screening attendance.
In 12% reduction compared with a no screening Breast cancer mortality reduction in the total German female population (all situation). In figure 1 the effect on total breast te to a screening programme for women aged 50-69 (two year screening interval) cancer mortality is shown for different levels of wd with different assumptions on sensitivity.
sensitivity achieved in a screening programme. A higher specificity will have favourable consequences for the women, since fewer women will be exposed to the anxiety of undergoing additional examination or even being referred for biopsy without breast cancer being diagnosed (table 3). In the baseline scenario almost 74 000 women will be subjected to additional examinations after a positive screen (3.3% of all screened women) in the year 1998, at the end of the build up phase. With a high specificity only 0.8% would have to be referred that year, which is 57 000 fewer women. Ten years later these figures will be more favourable since, by then, only a small portion of the screening examinations will be first screens, which have relatively high referral rates compared with subsequent screens (table 1) . The increase of specificity is expected to cause the yearly number of women referred for biopsy without breast cancer being diagnosed to be halved: 10 600 compared with 5400 in 1998; 7500 compared with 3600 in a steady state situation.
EXTRA COSTS AND COST EFFECTIVENESS
Costs and effects of the three scenarios for an age 50-69 years screening programme with a two year interval are displayed in table 4 (at a 5% discount rate to establish a time preference). The bulk of the costs (about DM 4.0 billion) is directly attributable to the screening programme as such (overhead costs, mammography). The main costs incurred by a programme are due to biopsies performed on women who are apparently without breast cancer (DM 576 million in the baseline scenario).
The main cost savings are due to treating fewer women with advanced disease (DM 889 million)25. The entry "Other costs" (DM 199 million) includes costs of diagnostic assessment in the programme, costs due to the increase in primary treatments and follow up, savings on diagnostic assessment outside the programme and savings on adjuvant therapies. Hence, in the baseline scenario almost DM 3.9 billion (discounted) needs to be spent to gain 207 000 life years (discounted): a cost effectiveness ratio of DM 19 000 per life year gained. A screening programme with high sensitivity and specificity is expected to be less expensive (DM 3.5 billion). The direct screening costs are about the same, but many fewer biopsies are performed on women without, breast cancer, and more money is saved on treatment of advanced disease. A high quality programme is also more effective (230 000 life years gained), resulting in a cost effectiveness ratio of DM 15 000 per life year gained. A low sensitivity screening programme leads to a ratio of more than DM 21 000 per life year gained.
In figure 2 it can be seen that varying the sensitivity has a large impact on the effects, but almost no impact on the total difference in costs. A higher sensitivity, while maintaining the level of positive predictive values, leads to more savings in terms of treatment of advanced disease, but also to extra costs incurred by a larger number of women referred, treated, and followed up. Consequently, a higher specificity can have a strong impact on costs, but will not increase the number of life years gained.
Discussion
It is of course difficult to make assumptions on the quality of a future population based screening programme in Germany that are based only on the available screening data from the German pilot projects. Using the MISCAN
Increasing sensitivity
The attendance rates used in the analyses are It is clear that the importance of sensitivity and specificity in a mass screening programme for breast cancer should not be underestimated. model we can analyse screening data by making The favourable and unfavourable effects for estimates for age specific detection rates, while the women involved are highly dependent on taking into account the underlying incidence the levels of sensitivity and specificity achieved. and clinical stage distribution of breast cancer Increasing sensitivity will lead to more detected and by comparing these with the observed rates. cases in an early stage, and thus to a more Because ofthe decentralised health care system effective programme with a higher number of in Germany, there is reason to believe that prevented breast cancer deaths. Also, with a the screening quality in Germany could be higher sensitivity more mastectomies can be improved. The results of the model, an ex-prevented in favour of breast conserving therpected 12% sensitivity difference compared apies. However, if specificity in the screening with The Netherlands, support this opinion, programme is low, these favourable effects are although there were no data on interval cancers. only achieved by referring a considerable numTo account for the uncertainty in assessing the ber of women for additional examinations and extent of this loss in quality, we have defined biopsies, thereby making the programme more two other sets of quality assumptions. The expensive. range of differences in sensitivity assumed for
In Germany, introducing a programme with the three German scenarios in this study was the baseline sensitivity and specificity assomewhat arbitrary, based on expert opinion, sumptions is expected to result in a total differbut seems plausible, considering the outcomes ence in costs of DM 3.9 billion (5% discount of the model. However, larger differences in rate). A high quality programme is expected quality between European countries might to lead to only DM 3.5 billion (discounted). exist.
Therefore, 11% of the total costs of a proThe various assumptions made about several gramme can be invested in quality assurance factors are, of course, open to discussion. For (in technique and interpretation), provided that instance, one could question how rep-the higher levels ofsensitivity and specificity can resentative the Saarland registry data on breast be achieved. In this way, an equally expensive cancer incidence rates are. National data on programme will gain an additional 24 000 life these incidence rates are lacking, but national years (5% discounted) and will prevent an breast cancer mortality rates closely resemble additional 200 cases of breast cancer death per those of the Saarland region. Furthermore, regional differences in incidence were assumed to be negligible on the basis of the regional mortality data for breast cancer. 
